论文部分内容阅读
Overall survival in COMBI-d, a randomized, double-blinded, phase Ⅲ study comparing the combination o
【作 者】
：
【机 构】
：
Melanoma Institute Australia and The University of Sydney, North Sydney, Australia
【出 处】
：
2015年临床肿瘤学新进展学术研讨会
【发表日期】
：
2015年3期
其他文献
A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibito
会议
会议
Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (p
会议
GADOLIN: Primary results from a phase Ⅲ study of obinutuzumab plus bendamustine compared with bendam
会议
Phase Ⅱ study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or doubl
会议
ELOQUENT-2: A phase Ⅲ, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/w
会议